Get it on Google Play

Clover begins phase 2 trial for respiratory combination vaccines

January 11, 2026 11:34 PM EST Send to a Friend
Clover Biopharmaceuticals Ltd. (HKEX: 02197) announced the completion of enrollment for the first participants in a Phase 2 clinical trial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login